VIVUS, Inc. (VVUS) And Auxilium Pharmaceuticals (AUXL) Announce FDA Acceptance Of Supplemental Filing Seeking An Update Of Prescribing Information For STENDRA (Avanafil)
1/21/2014 8:52:40 AM
MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., Jan. 21, 2014 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq:AUXL) today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental application that proposes to revise the STENDRA™ (avanafil) prescribing information with efficacy and safety information from Study TA-501, entitled "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men with Erectile Dysfunction." The PDUFA date for the supplemental filing is September 20, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by